Skip to content

Beam Therapeutics BEAM Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$247K-61.0%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$1.84M+184%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$1.18M-107%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Arrowhead Research logo
Arrowhead ResearchARWR
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$3.42B+24.5%

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beam Therapeutics's increase (decrease) in prepaid expense and other assets?
Beam Therapeutics (BEAM) reported increase (decrease) in prepaid expense and other assets of $31.86M in Q1 2026.
How has Beam Therapeutics's increase (decrease) in prepaid expense and other assets changed year-over-year?
Beam Therapeutics's increase (decrease) in prepaid expense and other assets increased by 65122.4% year-over-year, from -$49K to $31.86M.
What is the long-term trend for Beam Therapeutics's increase (decrease) in prepaid expense and other assets?
Over 2 years (2021 to 2025), Beam Therapeutics's increase (decrease) in prepaid expense and other assets has grown at a 145.9% compound annual growth rate (CAGR), from -$746K to -$4.51M.
What does increase (decrease) in prepaid expense and other assets mean?
This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.